Guidelines for the Timing of Asthma Plus Discontinuation in Children The goal of long-term management of asthma in children is to achieve good symptom control and maintenance of normal activity levels with minimal future risk.ICS is the drug of choice for the long-term management of asthma in children, and its efficacy and safety have been widely recognized by guidelines and evidence-based evidence. Because asthma is a chronic inflammatory disease of the airways, children with diagnosed asthma must be treated with long-term standardized therapy. The goal of long-term management of asthma in children is to achieve good symptom control and maintenance of normal activity levels with minimal future risk. 2015 GINA has clearly proposed a long-term management regimen for asthma in children aged 5 years and younger, which can be used in Tier 1 to Tier 4, depending on the severity of the disease, with daily low-dose ICS plus SABA as needed preferred in Tier 2. In Tier 3, doubling the low-dose ICS dose is preferred. The efficacy of the treatment regimen is evaluated and adjusted every 1-3 months, with maintenance for 3 months and downgrading if well controlled, consideration of escalation if partially controlled, and escalation or leapfrogging if not controlled. As the drug of choice for long-term management of childhood asthma, inhaled glucocorticoids (ICS) are effective in controlling asthma symptoms, improving quality of life, improving lung function, reducing airway inflammation and airway hyperresponsiveness, decreasing asthma exacerbations, and reducing asthma mortality. In children with mild persistent asthma, 0.5 mg/d nebulized inhalation budesonide treatment significantly improved daytime and nighttime symptoms and significantly improved lung function compared with placebo. In children with moderate persistent asthma, nebulized budesonide at 0.5-1 mg/d significantly controlled asthma symptoms compared to placebo. In addition, nebulized inhalation budesonide therapy significantly improved quality of life and significantly increased the duration of activity in children with asthma. Long-term, standardized ICS maintenance therapy can bring children with asthma to a state of good disease control, so when can the medication be stopped? The Chinese Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Children state that children on the lowest dose of ICS can be considered for discontinuation if their asthma is maintained under control and there is no recurrence of symptoms within 1 year. Studies have shown that most children with asthma can return to normal lung function 3 months after ICS treatment, but changes in airway responsiveness take a longer time. Therefore, it is recommended that an individualized discontinuation plan be proposed based on a 2-year course of therapy and/or 1 year of minimum ICS control without recurrence, taking into account other influencing factors such as lung function, airway responsiveness, FeNO, etc. For the safety of long-term ICS maintenance therapy, numerous evidence-based studies have demonstrated the safety of its application. Several studies have also confirmed that long-term treatment with the recommended dose of budesonide does not affect bone mineral density or height in children with asthma. In conclusion, children with diagnosed asthma must be treated with long-term standardized therapy, and ICS is the drug of choice for the long-term management of childhood asthma, and its efficacy and safety have been widely recognized by guidelines and evidence-based evidence.